Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7544-7551

  Wang, L G ^a   Ossowski, L ^a   Ferrari, A C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; METRIBOLONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN P21;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA METHYLATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

APOPTOSIS; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 0035887451     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Androgen receptor gene and hormonal therapy failure of and prostate cancer
2. Studies on prostatic cancer 1: The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
3. Studies on prostatic cancer: 11. The effects of castration on advanced carcinoma of the prostate gland
4. Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation
5. Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative
6. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation
7. Distant metastases from prostatic carcinoma express androgen receptor protein
8. Androgen receptor status of lymph node metastases from prostate cancer
9. Molecular cloning of human prostate specific antigen cDNA
10. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
11. Prostate specific antigen in hormonally treated D2 prostate cancer: Is it always an accurate indicator of disease status?
12. Serum PSA after antiandrogen therapy
13. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
14. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
15. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers
16. Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma
17. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression
18. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process
19. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence
20. Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer
21. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression
22. Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa)
23. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma
24. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element
25. Many transcription factors interact synergistically with steroid receptors
26. Synergism between androgens and protein kinase-C on androgen-regulated gene expression
27. Functional analysis of the transforming growth factor β responsive elements in the WAF1/Cip1/p21 promoter
28. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites
29. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines
30. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells
31. Hormone-dependent androgen receptor phosphorylation is accompanied by receptor transformation in human lymph node carcinoma of the prostate cells
32. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones
33. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity
34. DNA hypermethylation in tumorigenesis: Epigenetics joins genetic
35. Altering gene expression with 5-azacytudune
36. Kip1 in androgen-induced cell cycle arrest
37. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
38. CDK inhibitors: Positive and negative regulators of G1-phase progression
39. Androgen induction of cyclin-dependent kinase inhibitor p21 gene: Role of androgen receptor and transcription factor Sp1 complex
40. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter
41. WAF1/CIP1 expression in normal and neoplastic tissues
42. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides
43. Selective induction of cyclin-dependent kinase inhibitors and their roles in cell cycle arrest caused by trichostatin A, an inhibitor of histone deacetylase
44. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
45. Androgen receptor - An update of mechanisms of action in prostate cancer
46. Activation and repression by nuclear hormone receptors: Hormone modulates an equilibrium between active and repressive states
47. Identification and characterization of a suppressor element in the 5′-flanking region of the mouse androgen receptor gene
48. The mouse androgen receptor is suppressed by the 5′-untranslated region of the gene
49. Negative regulation of the androgen receptor gene promoter by NF1 and an adjacently located multiprotein-binding site
50. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
51. Cloning and characterization of a specific coactivator. ARA70, for the androgen receptor in human prostate cells
52. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells